Search
27/10/2023
Frontline therapy in Chronic Lymphocytic Leukemia
Arguello-Tomas, M, Albiol, N, Moreno, C. Frontline therapy in Chronic Lymphocytic Leukemia. ACTA HAEMATOLOGICA. 2023; 147(1)DOI:10.1159/000534730. PMID:37899041. IF:1.700(Q3/8D).
26/10/2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Kwatra, SG, Yosipovitch, G, Legat, FJ, Reich, A, Paul, C, Simon, D, Naldi, L, Lynde, C, De Bruin-Weller, MS, Nahm, WK, Sauder, M, Gharib, R, Barbarot, S, Szepietowski, JC, Conrad, C, Fleischer, A, Laquer, VT, Misery, L, Serra-Baldrich, E, Lapeere, H, Ahmad, F, Lopez, ZKJ, Piketty, C, Ständer, S. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(17)DOI:10.1056/NEJMoa2301333. PMID:37888917. IF:96.300(Q1/1D).
25/10/2023
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort
Broers, MC, Wieske, L, Erdag, E, Gürlek, C, Bunschoten, C, van Doorn, PA, Eftimov, F, Kuitwaard, K, de Vries, JM, de Wit, MCY, Nagtzaam, MMP, Franken, SC, Zhu, LIS, Paunovic, M, de Wit, M, Schreurs, MWJ, Lleixà, C, Martín-Aguilar, L, Pascual-Goñi, E, Querol, L, Jacobs, BC, Huizinga, R, Titulaer, MJ. Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2023; 95(1)DOI:10.1136/jnnp-2023-331378. PMID:37879898. IF:8.800(Q1/1D).
25/10/2023
A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study
Escobar, C, Freire, RB, Marimón, XGM, González-Juanatey, C, Morillas, M, Muñoz, AV, Doblas, JJG. A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study. Cardiovascular Diagnosis and Therapy. 2023; 13(5)DOI:10.21037/cdt-23-76. PMID:37941839. IF:2.000(Q3/6D).
25/10/2023
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis
Juanola, A, Ma, AT, de Wit, K, Gananandan, K, Roux, O, Zaccherini, G, Jiménez, C, Tonon, M, Solé, C, Villaseca, C, Uschner, FE, Graupera, I, Pose, E, Moreta, MJ, Campion, D, Beuers, U, Mookerjee, RP, Francoz, C, Durand, F, Vargas, V, Piano, S, Alonso, S, Trebicka, J, Laleman, W, Asrani, SK, Soriano, G, Alessandria, C, Serra-Burriel, M, Morales-Ruiz, M, Torres, F, Allegretti, AS, Krag, A, Caraceni, P, Watson, H, Abraldes, JG, Sola, E, Kamath, PS, Hernaez, R, Ginès, P, LiverHope Investigators. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis. GUT. 2023; DOI:10.1136/gutjnl-2023-329923. PMID:37884354. IF:23.100(Q1/1D).
23/10/2023
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
Valero-Martínez, C, Urgelles, JF, Sallés, M, Joven-Ibáñez, BE, de Juanes, A, Ramírez, J, Juanola, X, Almodóvar, R, Laiz, A, Moreno, M, Pujol, M, Beltrán, E, Pinto-Tasende, JA, Crespí, L, Sala-Icardo, L, Castañeda, S, García-Vicuña, R. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1283251. PMID:37936691. IF:5.700(Q1/3D).
21/10/2023
Hyperactive delirium during emergency department stay: analysis of risk factors and association with short-term outcomes
Miró Ò., Osorio G., Alquézar-Arbé A., Aguiló S., Fernández C., Burillo G., Jacob J., Llorens P., Llauger L., Peláez González Á., Figuera Castro E.R., Juarez González R., Blanco Hoffman M.J., Fernandez Salgado F., Pablos Pizarro T., Berenguer Díez M.A., Truyol Más M., López-Laguna N., Garcia Acosta J., Fernandez Domato C., Diego Robledo F.J., Ezponda P., Martinez Lorenzo A., Ortega Liarte J.V., García Rupérez I., Borne Jerez S., Corugedo Ovies C., Gallardo Sánchez B.A., Del Castillo J.G.. Hyperactive delirium during emergency department stay: analysis of risk factors and association with short-term outcomes. Internal and Emergency Medicine. 2023; 19(2)DOI:10.1007/s11739-023-03440-3. PMID:37865623. IF:3.200(Q1/2D).
21/10/2023
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socié G., Barba P., Barlev A., Sanz J., García-Cadenas I., Chevallier P., Fagioli F., Guzman-Becerra N., Kumar D., Ljungman P., Pigneux A., Sadetsky N., Yáñez San Segundo L., Shadman M., Storek J., Thirumalai D., Xing B., Mohty M.. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. BONE MARROW TRANSPLANTATION. 2023; 59(1)DOI:10.1038/s41409-023-02127-9. PMID:37865719. IF:4.500(Q1/2D).